Neurobiological Technologies, Inc. Stock Other OTC

Neurobiological Technologies, Inc. (NTI), was previously focused on developing investigational drugs to treat human diseases. On October 27, 2009, the Company’s stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company. On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.